Operating CF
$4.24B
Capex
−$530.30M
Free Cash Flow
$3.71B
FCF Margin
+87.5%
Cash flow waterfall for Vertex Pharmaceuticals (VRTX) — TTM through Q1 2026
Free cash flow: $3.71B
Cash flow breakdown for Vertex Pharmaceuticals (VRTX) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Operating Cash Flow | $4.24B | $4.24B |
| Capital Expenditure | −$530.30M | $3.71B |
| Free Cash Flow | $3.71B | $3.71B |
| Other Investing | −$791.20M | $2.92B |
| Share Buybacks | −$1.93B | $988.40M |
| Other Financing & FX | −$168.90M | $819.50M |
| Net Cash Increase | $819.50M | $819.50M |
- Operating Cash Flow$4.24B
- Capital Expenditure−$530.30M
- Free Cash Flow$3.71B
- Other Investing−$791.20M
- Share Buybacks−$1.93B
- Other Financing & FX−$168.90M
- Net Cash Increase$819.50M
Want to see what drove the FCF change?Free Cash Flow Bridge
Frequently asked questions
Data & methodology
Vertex Pharmaceuticals (VRTX) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement